Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modified vaccinia Ankara HIV vaccine
- Development stage
- Unknown
- Lead developer
- Swedish Institute for Infectious Disease Control
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
The modified vaccinia Ankara (MVA) HIV vaccine (specifically the MVA-CMDR construct) is a recombinant viral vector-based vaccine developed by the U.S. Military HIV Research Program (MHRP), the Walter Reed Army Institute of Research (WRAIR), and the National Institute of Allergy and Infectious Diseases (NIAID). It has been clinically evaluated by the Swedish Institute for Infectious Disease Control (SMI) and the Karolinska Institutet. The vaccine utilizes a highly attenuated, replication-deficient Modified Vaccinia Ankara virus as a vector to deliver HIV-1 antigens, specifically expressing subtype E Env (gp150) and subtype A Gag/Pol from Thai isolates CM235 and CM240. In the HIVIS 01/02 and HIVIS 03 trials, the vaccine was evaluated as a heterologous booster following priming with a multigene HIV-1 plasmid DNA vaccine (HIVIS-DNA) in healthy, HIV-negative adults to elicit both robust humoral and cellular immune responses for the prevention of HIV infection.
- Other names
- MVA HIV vaccineHIV-MVAMVA-Chiang Mai double recombinant
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)Human immunodeficiency virus type 1 reverse transcriptaseGag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on modified vaccinia Ankara HIV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modified vaccinia Ankara HIV vaccine.